Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586211 | 1.00 | HIF1A (0.49) | HIF1AEPAS1HRH3SMN1; SMN2LMNA | |
| SCHEMBL578573 | 0.95 | HIF1A (0.53) | HIF1AEPAS1HRH3SMN1; SMN2LMNA | |
| SCHEMBL578572 | 0.95 | HIF1A (0.53) | HIF1AEPAS1HRH3SMN1; SMN2LMNA | |
| SCHEMBL578448 | 0.90 | HRH3 (0.46) | HIF1AEPAS1HRH3ALDH1A1 | |
| SCHEMBL578449 | 0.90 | HRH3 (0.46) | HIF1AEPAS1HRH3ALDH1A1 | |
| SCHEMBL585850 | 0.89 | HRH3 (0.49) | HRH3ALDH1A1 | |
| SCHEMBL585851 | 0.89 | HRH3 (0.49) | HRH3ALDH1A1 | |
| SCHEMBL585632 | 0.83 | SIGMAR1 (0.44) | HIF1AEPAS1HRH3SMN1; SMN2LMNA | |
| SCHEMBL585631 | 0.83 | SIGMAR1 (0.44) | HIF1AEPAS1HRH3SMN1; SMN2LMNA | |
| SCHEMBL4110423 | 0.83 | LMNA (0.47) | HIF1AEPAS1LMNAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| EP-2556071-B1 | KINASE INHIBITORS AND THEIR USE IN TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2016-08-17 | — | — | EP | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| US-9139563-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2015-09-22 | — | — | US | disclosed |
| US-8999968-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2015-04-07 | — | — | US | disclosed |
| EP-2417127-B1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| EP-2556071-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2013-02-13 | — | — | EP | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2011123946-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | HIF1A 1529/4885EPAS1 3138/4885HRH3 3894/4885 |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HIF1A 1612/4885EPAS1 2975/4885HRH3 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.